Highlights Valneva Xetra

Equities

Real-time Estimate Tradegate Other stock markets 12:38:27 28/06/2024 pm IST			5-day change	1st Jan Change
3.247 ^EUR	-1.43%		+4.24%	-30.64%

26/06	Valneva SE Appoints Daniele Guyot-Caparros as Board of Directors	CI
24/06	Valneva's Chikungunya Vaccine Receives Health Canada's Approval	MT

Valneva rises after Canadian approval for its chikungunya vaccine	24/06	RE
Valneva Secures Canadian Approval for Chikungunya Vaccine	24/06	MT
Europe opens hesitant as metal prices fall	24/06	RE
Pfizer: article on Lyme vaccine in The Lancet	04/06	CF
Valneva: article on Lyme vaccine in The Lancet	04/06	CF
Valneva SE Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases	03/06	CI
Valneva's Chikungunya Vaccine Gains Support From EU Regulator Committee	31/05	MT
Valneva SE Receives EMA?s Positive CHMP Opinion for its Chikungunya Vaccine	31/05	CI
EU regulator recommends use of Valneva's chikungunya vaccine	31/05	RE
Valneva: new positive data in CHIKV	13/05	CF
Valneva SE Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
Europe rises, buoyed by financial results	07/05	RE
Valneva: quarterly results boosted by PRV sale	07/05	CF
Valneva posts Q1 profit of EUR58.9 mlns	07/05	RE
Valneva SE Confirms Earnings Guidance for the Fiscal Year 2024	07/05	CI
Valneva: Deep Track Biotechnology Master holds less than 5% of the capital	11/04	CF
Valneva Kicks Off Early-stage Trial for Zika Vaccine Candidate	26/03	MT
Valneva: Phase 1 trial initiated in the Zika virus	26/03	CF
Valneva SE Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate	26/03	CI
ADRs End Higher; XTL Biopharmaceuticals Climbs 129%	21/03	DJ

No results for this search